Phathom Pharma Files Q1 2025 10-Q
Ticker: PHAT · Form: 10-Q · Filed: May 1, 2025 · CIK: 1783183
| Field | Detail |
|---|---|
| Company | Phathom Pharmaceuticals, Inc. (PHAT) |
| Form Type | 10-Q |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financing, financials
TL;DR
Phathom Pharma's Q1 2025 10-Q is in. Check R&D and financing details.
AI Summary
Phathom Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance, including research and development expenses and revenue interest financing agreements. Key dates mentioned include May 1, 2025, for the filing date and March 31, 2025, for the reporting period.
Why It Matters
This filing provides insight into Phathom Pharmaceuticals' financial health and operational activities during the first quarter of 2025, which can influence investor decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Phathom is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial performance)
- 20250331 — Period End Date (The end date for the financial data presented)
- 20250501 — Filing Date (The date the report was officially submitted to the SEC)
Key Players & Entities
- Phathom Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250501 (date) — Filing date
- Sagard (company) — Mentioned in relation to financing
- Hercules (company) — Mentioned in relation to financing
FAQ
What were Phathom Pharmaceuticals' research and development expenses for the first quarter of 2025?
The filing indicates that us-gaap:ResearchAndDevelopmentExpenseMember was reported for the period 2024-01-01 to 2024-03-31, and also for 2025-01-01 to 2025-03-31, but specific dollar amounts are not detailed in this excerpt.
What is the nature of the 'Revenue Interest Financing Agreement' mentioned?
The filing mentions phat:RevenueInterestFinancingAgreementMember, indicating a financing agreement related to revenue, but details are not provided in this excerpt.
Who are the key investors or financing partners mentioned in the filing?
The filing mentions 'InitialInvestorsNqSagardAndHerculesMember', suggesting Sagard and Hercules are involved as initial investors or financing partners.
What is the significance of the 'Loan Agreement' and 'Term Loans Aggregate Principal Amount Tranches Three'?
The filing references phat:LoanAgreementMember and phat:TermLoansAggregatePrincipalAmountTranchesThreeMember, dated 2024-06-14, indicating a loan agreement with specific tranches, but the principal amounts are not detailed here.
Does the filing mention any specific product lines or customer concentration risks?
Yes, the filing mentions us-gaap:SalesRevenueProductLineMember and us-gaap:CustomerConcentrationRiskMember for the period 2025-01-01 to 2025-03-31, and also us-gaap:AccountsReceivableMember and us-gaap:CustomerConcentrationRiskMember for the same period, suggesting these are areas of focus.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding Phathom Pharmaceuticals, Inc. (PHAT).